Navigation Links
Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
Date:1/28/2008

ies. Mr. Bennett earned his MBA from Pepperdine University and his B.S. in Industrial Technology from California State University, Long Beach.

"I am very excited to join Allos and lead the Company's manufacturing activities," said Mr. Bennett. "I believe Allos has the product candidates and leadership team to make a potentially significant impact in the development of new therapies for the treatment of cancer."

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins Lymphoma (NHL). For additional information, please visit the Company's website at http://www.allos.com.

Safe Harbor Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements relating to Mr. Bennett's potential impact on the future growth and success of the Company; the potential safety, efficacy and marketability of the Company's product candidates; and other statements that are other than statements of historical facts. In some cases, you can identify forward-looking s
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference
2. Allos Therapeutics Reports Third Quarter 2007 Financial Results
3. Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
4. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
5. Transition Therapeutics Announces Appointment of Vice-President of Business Development
6. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
7. Transition Therapeutics Announces Milestone Payment from Elan
8. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
9. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
10. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
11. Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2015)... (PRWEB) May 03, 2015 Looking ... that will directly impact your career? The Master ... for dynamic leaders in multinational companies and for ... In a changing global landscape, differences in culture, ... relationships. The EMIB program develops the global competence ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company ... appearance at the , May 5 - 7, 2015 ... exhibit at the conference include its bestselling TaskMate sit ... is the 6100 TaskMate Executive. Features of the 6100 ... keyboard tray, extended platform work surface and supply holders. ...
(Date:5/2/2015)... 02, 2015 “ ActOn ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... connected with organizations to make a difference. , In this ... few things that aren’t about money, which is why those ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured on NewsWatch ... the latest and coolest technology products available to consumers. ... NewsWatch, conducted the review and shared with viewers how ... is an important part of people’s lives – and ... royal treatment. Peachtree Audio does just that with high-end ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare ... its new healthcare insurance to individuals and small businesses ... System is the nation’s first health insurance system built ... Personal Health Insurance was ZoomCare’s first such filing including ... to review and regulation by the Oregon Insurance Division. ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... hotel-style room service to massage therapy to magnificent views, ... bid to gain market share, especially those in competitive ... the New England Journal of Medicine , raises ... care, explaining that how we decide to value the ...
... fatal brain conditions such as mad cow disease in ... the horizon, according to a new study from National ... of Allergy and Infectious Diseases (NIAID) have developed a ... measure infectious agents called prions that cause these diseases. ...
... Healthcare has produced the first results in humans of a ... aggressiveness of prostate tumors in real time, by imaging the ... used this technology to conduct real-time metabolic imaging in human ... outlines of a tumor, its response to treatment and how ...
... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... that measures the circuitry of brain connections may someday be ... McLean Hospital in Boston and the University of Utah used ... the brain circuitry in 30 males aged 8 to 26 ...
... crucial for regulating the self-renewal of normal prostate stem ... cells killed by hormone withdrawal therapy for cancer, also ... cells, researchers at UCLA have found. The findings, ... of Regenerative Medicine and Stem Cell Research at UCLA, ...
... inaugural James W. Varnum National Quality Award was presented ... Medical Center (CCHMC), in a ceremony held on Wednesday, ... Hampshire. , Receiving the award were Project SEARCH ... Disability Services; and Dr. Linda Workman, Vice President of ...
Cached Medicine News:Health News:Hospital perks: How much should hospitals be rewarded for the patient experience? 2Health News:NIH study suggests that early detection is possible for prion diseases 2Health News:NIH study suggests that early detection is possible for prion diseases 3Health News:'Watchful waiting' has a new set of eyes 2Health News:'Watchful waiting' has a new set of eyes 3Health News:'Watchful waiting' has a new set of eyes 4Health News:Brain Scan Might Someday Spot Autism 2Health News:Brain Scan Might Someday Spot Autism 3Health News:UCLA scientists discover mechanism that turns healthy cells into prostate cancer cells 2Health News:James W. Varnum National Quality Award presented to Project SEARCH 2Health News:James W. Varnum National Quality Award presented to Project SEARCH 3
(Date:5/1/2015)... 2015  Boston Scientific Corporation (NYSE: BSX ) ... and long-term growth strategies at a meeting with the ... . President and Chief Executive Officer Mike ... has to bring forward meaningful innovation to transform patient ... shareholder value. "We are focused on ...
(Date:5/1/2015)... , May 1, 2015  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... debridement, cosmetic surgery, laparoscopic surgery and other surgical ... results for the third quarter fiscal year 2015 ... scheduled a conference call that same day, Thursday, ...
(Date:5/1/2015)... RUTHERFORD, N.J., May 1, 2015 Cambrex Corporation (NYSE: ... March 31, 2015. Highlights , ... and increased 27% excluding foreign currency impact, driven by Innovator ... million from $8.4 million in the first quarter of 2014. ... versus $0.04 in the first quarter last year and Adjusted ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) reported ... detailed analyses supporting the dosing,regimen in NTI,s two ... stroke. The company also provided information as to ... be successful in treating,ischemic stroke than previous Phase ...
... May 14 The Quigley,Corporation (Nasdaq: QGLY ... its wholly owned subsidiary, Quigley Pharma Inc., which ... of its compound,QR448(a). The compound was administered to ... (IBV). The data from the study indicated,that QR448(a) ...
Cached Medicine Technology:Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 2Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 3Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 3Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 5
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: